HBM Healthcare Investments
Crossover fundZug · Growth–Late Stage · 7 people tracked
Find your way into HBM Healthcare Investments
239 people in our graph share verified history with the HBM Healthcare Investments team — schools, employers, funds. One of them is your warm intro.
Investment thesis
HBM Healthcare Investments targets the global healthcare sector, which it views as a large and fast-growing economic area driven by demographic change (population growth and aging), medical progress and innovation, rising prosperity in emerging markets, and improved access to medical products and services. It maintains a globally diversified portfolio spanning both private and publicly listed healthcare companies, aiming for attractive long-term performance in net asset value (NAV) per share and share price. The firm has historically delivered a distribution yield of roughly 3 to 5 percent per year.
Source: firm website, verified Aug 3, 2026.
Team · 7 people
from the firm's website & public directories
What they invest in
from 13 of 14 portfolio companiesBiotech ×10Healthtech ×7Medical Devices ×3E-commerce ×1Logistics & Supply Chain ×1SaaS ×1
HQs:United States×10Switzerland×1Netherlands×1
Investments · 14 tracked
founders shown can be your intro pathBy year:2026 · 12024 · 12022 · 12020 · 22017 · 22016 · 18 dated
Amphora provides logistics services aimed at supporting business growth and operational efficiency.
E-commerceLogistics & Supply ChainSaaS
Joan Tresserras(Founder)inAdrià Cortés(Founder)in
Co-investorsBStartupBaird CapitalF-Prime CapitalLongitude Capital
BiotechEvanston, US
Joseph R. Moskal(Chief Scientific Officer)Torsten M. Madsen(Chief Marketing Officer)Ashish Khanna(Secretary & Chief Business Officer)Norbert G. Riedel(Chief Executive Officer)
BoardLiam Ratcliffe(Director)Terry P. Gould(Director)
Co-investorsBain Capital Life SciencesFrazier Life SciencesLatterell Venture PartnersLongitude CapitalOUP (Osage University Partners)Agent Capital+2 more
Biohaven is a biopharmaceutical company that discovers, develops, and commercializes treatments across immunology, obesity, neuroscience, and oncology, targeting rare and common diseases with limited treatment options.
BiotechHealthtech
Vlad Coric(Chairman & Chief Executive Officer)in
Co-investorsAisling CapitalAPERTURE Venture PartnersConnecticut InnovationsOUP (Osage University Partners)OrbiMed
Healthcare company acquired by Mirum Pharmaceuticals, a former RiverVest portfolio company.
San Mateo, US
Keting Chu(Executive Officer, Director)inDajun Yang(Director)Nancy Hong(Director)inAlon Lazarus(Director)William J. Rutter(Director)Ting Jia(Director)
Co-investorsFrazier Life SciencesRA CapitalRiverVest Venture PartnersNovo HoldingsT. Rowe PriceWellington Management
Curevo Vaccine is a biotech company developing next-generation non-mRNA vaccines, with a focus on infectious diseases.
BiotechHealthtech
George Simeon(CEO)inGregory S. Curhan(CFO)Guy De La Rosa(CMO)in
Co-investorsAdjuvant CapitalOrbiMedRA CapitalSanofi VenturesJanus Henderson InvestorsMedicxi
Dren Bio is a clinical-stage biopharmaceutical company developing novel antibody therapeutics designed to selectively eliminate pathogenic cells and disease-causing agents, with a pipeline targeting oncology, autoimmune diseases, immunology, and neurology.
BiotechHealthtechMedical DevicesFoster City, US
Nenad Tomasevic(Chief Executive Officer, Founder)
BoardIvan Trifunovich(Director)John Wesley(Director)
Co-investors8VCAisling CapitalMission Bay CapitalMission BiocapitalOlive Tree CapitalSR One Capital Management+3 more
Clinical-stage genetic medicines company using human-derived AAV vectors and nuclease-free gene editing for rare diseases.
BiotechBedford, US
Siyamak Rasty(Executive Officer)Albert Seymour(Executive Officer)
BoardSteven Gillis(Director)Arthur Tzianabos(Executive Officer, Director)Kush Parmar(Director)inRichard Gregory(Director)
Co-investors5AM VenturesARCH Venture PartnersOUP (Osage University Partners)AlexandriaDeerfield Management CompanyMaverick Ventures+4 more
IOBiotech appears to be a biotech company focused on oncology, with a founder who has extensive experience in cancer drug development and clinical advancement from roles at Roche, Eli Lilly, and leading academic cancer centers.
BiotechMedical Devices
Dr. Dhingra
Co-investorsAvoro Capital AdvisorsEIR VenturesKurma PartnersRA CapitalSamsara BioCapitalSunstone Capital+2 more
Lycia Therapeutics is a biotechnology company developing LYTAC (Lysosomal Targeting Chimera) therapeutics that bind disease-causing extracellular and cell-surface proteins and route them into the cell's lysosome for degradation.
BiotechHealthtechSouth San Francisco, US
Aetna Wun Trombley(President and CEO)inAmy Bachrodt(Chief Financial Officer)inChin Lee(Chief Medical Officer)inSteve Staben(Chief Scientific Officer)inSofia Touami(Chief Business Officer)inKaren Flick(General Counsel)in
Co-investorsREDMILEVersant VenturesBAM ElevateFranklin TempletonInvusJanus Henderson Investors+4 more
Swixx BioPharma is a specialized pharmaceutical distributor and market access partner that represents international biopharma, OTC, and medical device companies in markets across Central & Eastern Europe, the Middle East, North Africa, Latin America, and Eurasia.
BiotechHealthtechMedical DevicesBaar, CH
Co-investorsBain Capital Life SciencesHBM PartnersMérieux Equity PartnersSK Capital Partners
Other
Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.
Amphora MedicalComplexaSymbiomix TherapeuticsVascular Dynamics
Exits · 3
1 IPOs · 2 acquisitions · showing 2Amphora Medicalacq. by HologicBluejay Therapeuticsacq. by Mirum Pharmaceuticals
Portfolio news
latest coverage across their companies
Lycia Therapeutics · intelligence360.news · Jul 22, 2026
IO Biotech · european-biotechnology.com · Apr 2, 2026
Biohaven Pharmaceuticals · investing.com · Mar 3, 2026
Dren Bio · biospace.com · Mar 2, 2026
Swixx Biopharma · investorsinhealthcare.com · Dec 15, 2025
Amphora · privateequitycareer.com · May 27, 2025
Curevo Vaccine · clinicaltrialvanguard.com · Mar 18, 2025
Frequently asked questions
- How many investments has HBM Healthcare Investments made?
- HBM Healthcare Investments has 14 tracked investments, 3 of which have exited, including 1 dated in the last 24 months.
- What stage does HBM Healthcare Investments invest at?
- HBM Healthcare Investments invests at the Growth, Late Stage stages.
- What sectors does HBM Healthcare Investments focus on?
- HBM Healthcare Investments focuses on Biotech, Digital Health, Healthtech, Longevity, Medical Devices.
- Where is HBM Healthcare Investments located?
- HBM Healthcare Investments is headquartered in Zug, CH.
Similar investors
GV (Google Ventures) is a venture capital firm that has invested in artificial intelligence and machine learning since its early days, building a global portfolio of more than 100 AI companies across infrastructure, life sciences, and applications.
Khosla Ventures is a venture capital firm founded by Vinod Khosla.
EQT Life Sciences, formerly LSP (Life Sciences Partners), is one of Europe's largest and most experienced life sciences investors, backing companies developing therapeutics, medical devices, diagnostics and healthtech.
5AM Ventures is a life science venture capital firm founded in 2002 that invests primarily in private therapeutic companies, with a focus on biopharmaceuticals, drug delivery technologies, and life science instruments.
Gore Range Capital is a specialized healthcare investment firm building science-led platforms across precision health, regenerative medicine, personalized therapeutics, and longevity. It provides strategic, financial, and clinical guidance to portfolio companies developing next-generation healthcare solutions.